Bristol-Myers Squibb is a biopharmaceutical company operating in a single segment engaged in discovering, developing, licensing, manufacturing, marketing, and selling innovative medicines in oncology, hematology, immunology, cardiovascular, and neuroscience. Products are sold worldwide to wholesalers, distributors, specialty pharmacies, hospitals, clinics, government agencies, and directly to patients.
BMS generated total revenues of $48.2 billion in 2025, approximately 69% from the United States. The company maintains manufacturing operations in the U.S., Puerto Rico, the Netherlands, Ireland, and Switzerland. In 2025 it acquired Orbital Therapeutics and entered collaboration agreements with BioNTech and Philochem. It competes with global research-based pharmaceutical companies, smaller biotech firms, and generic drug manufacturers.
US 69% · Non Us 29% · Other Region 2%
geographic · FY2025 (ended Dec 2025) · share of tagged segment revenue (10-K XBRL, as filed)
